2025 Q4 -tulosraportti
Vain PDF
70 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 73 | - | - | ||
| 250 | - | - | ||
| 4 | - | - | ||
| 40 | - | - | ||
| 286 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 659 | 14 659 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 659 | 14 659 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 22.1. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 23.4.2025 | ||
2024 Q4 -tulosraportti 23.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8.3.Dagens industri reiterates its buy recommendation for Bengt Julander's investment company Linc. Contains unique investment opportunities, is diversified and trades at a discount to net asset value. https://nyemissioner.se/nyheter/investmentbolaget-linc-ar-fortsatt-kopvart-anser-dagens-industri/
·26.2.Interesting situation!i Linc? Large insider purchases recently and that they own approx. 15% of Medivir which has surged approx. 240 % while Linc has only moved a 5-7%. Realized some of the profit in Medivir and bought Linc today.
·25.2.Updated 25.02.2026 Is Linc still a good offer, after the share has risen 14-15 % from its low point to its high point in the last month? And when the price of Medcap keeps falling right now. When checking ibindex.se today, their calculation of the NAV discount on Linc now only shows 6 % at a share price as of today of 66.90 SEK. But that's not how I calculate the discount, as I instead use what I call the “real NAV discount”, and thus arrive at 63 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares as well as positive capital including receivables (and offsetting any debt.) So right now, you get the unlisted shares in Linc’s portfolio for one third of the valuation. (Today I have deleted a number of previous posts, as they were based on a NAV and a discount that were much higher at the time, so no one is “tricked” into believing that the discount is as large as it was when I wrote the post.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know that, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. It can be noted that there are significant insider purchases, which have probably contributed to the price increase recently. But since the 15 unlisted shares in Linc only constitute approx. 10 % of the total NAV, it doesn't really matter much for this stock if one or two of these shares should be overpriced or go bankrupt. Another prerequisite is, of course, that one is comfortable with whether the daily price of the listed shares will hold up in the future to the same extent as other shares on the market, or whether one assesses that some of them have serious hidden problems. Others than me may have greater abilities to assess the value of the underlying unlisted companies. But an important detail is that Medcap accounts for 1/3 of the value in the Linc share. Medcap is relatively lowly priced at the moment, which can provide upside potential. If, on the other hand – dramatically – one assesses that the share could go bankrupt and end at 0 SEK, then it corresponds to the price of Linc being 29 % too high. But that is hardly a scenario anyone can imagine. But I choose to continuously monitor the price development in Medcap to assess Linc. I myself think it is an advantage to be invested in Medcap via Linc, so I have a large insurance through the diversification in Linc instead of being directly invested in Medcap myself – but that is probably a matter of taste. Is Linc still a good offer? Yes, I think so myself, based on an expectation that Medcap's price will rise again and that insiders, through their purchases, show their confidence in Linc. If one does not share these views, the matter is different. Linc is a somewhat peculiar stock. In periods, one pays an overprice, and in other periods, one gets a large discount. There are no fundamental reasons for the fluctuations, so one simply has to get used to them - and use them in one's buy and sell strategy. One of the very good things about this stock is that you don't have to worry about a dilutive rights issue, as we have seen in e.g. Karolinska Development and First Venture. On the contrary. The coffers are full.- 25.2.25.2.Tämä julkaisu on poistettu.·23.1.So Affärsvärlden also entered the arena: is pointed out by Affärsvärlden as a healthy alternative in a long-term portfolio. Affärsvärlden issues a buy recommendation for Linc and states that the share is now trading at a record-high discount.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
70 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8.3.Dagens industri reiterates its buy recommendation for Bengt Julander's investment company Linc. Contains unique investment opportunities, is diversified and trades at a discount to net asset value. https://nyemissioner.se/nyheter/investmentbolaget-linc-ar-fortsatt-kopvart-anser-dagens-industri/
- ·26.2.Interesting situation!i Linc? Large insider purchases recently and that they own approx. 15% of Medivir which has surged approx. 240 % while Linc has only moved a 5-7%. Realized some of the profit in Medivir and bought Linc today.
- ·25.2.Updated 25.02.2026 Is Linc still a good offer, after the share has risen 14-15 % from its low point to its high point in the last month? And when the price of Medcap keeps falling right now. When checking ibindex.se today, their calculation of the NAV discount on Linc now only shows 6 % at a share price as of today of 66.90 SEK. But that's not how I calculate the discount, as I instead use what I call the “real NAV discount”, and thus arrive at 63 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares as well as positive capital including receivables (and offsetting any debt.) So right now, you get the unlisted shares in Linc’s portfolio for one third of the valuation. (Today I have deleted a number of previous posts, as they were based on a NAV and a discount that were much higher at the time, so no one is “tricked” into believing that the discount is as large as it was when I wrote the post.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know that, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. It can be noted that there are significant insider purchases, which have probably contributed to the price increase recently. But since the 15 unlisted shares in Linc only constitute approx. 10 % of the total NAV, it doesn't really matter much for this stock if one or two of these shares should be overpriced or go bankrupt. Another prerequisite is, of course, that one is comfortable with whether the daily price of the listed shares will hold up in the future to the same extent as other shares on the market, or whether one assesses that some of them have serious hidden problems. Others than me may have greater abilities to assess the value of the underlying unlisted companies. But an important detail is that Medcap accounts for 1/3 of the value in the Linc share. Medcap is relatively lowly priced at the moment, which can provide upside potential. If, on the other hand – dramatically – one assesses that the share could go bankrupt and end at 0 SEK, then it corresponds to the price of Linc being 29 % too high. But that is hardly a scenario anyone can imagine. But I choose to continuously monitor the price development in Medcap to assess Linc. I myself think it is an advantage to be invested in Medcap via Linc, so I have a large insurance through the diversification in Linc instead of being directly invested in Medcap myself – but that is probably a matter of taste. Is Linc still a good offer? Yes, I think so myself, based on an expectation that Medcap's price will rise again and that insiders, through their purchases, show their confidence in Linc. If one does not share these views, the matter is different. Linc is a somewhat peculiar stock. In periods, one pays an overprice, and in other periods, one gets a large discount. There are no fundamental reasons for the fluctuations, so one simply has to get used to them - and use them in one's buy and sell strategy. One of the very good things about this stock is that you don't have to worry about a dilutive rights issue, as we have seen in e.g. Karolinska Development and First Venture. On the contrary. The coffers are full.
- 25.2.25.2.Tämä julkaisu on poistettu.·23.1.So Affärsvärlden also entered the arena: is pointed out by Affärsvärlden as a healthy alternative in a long-term portfolio. Affärsvärlden issues a buy recommendation for Linc and states that the share is now trading at a record-high discount.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 73 | - | - | ||
| 250 | - | - | ||
| 4 | - | - | ||
| 40 | - | - | ||
| 286 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 659 | 14 659 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 659 | 14 659 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 22.1. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 23.4.2025 | ||
2024 Q4 -tulosraportti 23.1.2025 |
2025 Q4 -tulosraportti
Vain PDF
70 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 22.1. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 23.4.2025 | ||
2024 Q4 -tulosraportti 23.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8.3.Dagens industri reiterates its buy recommendation for Bengt Julander's investment company Linc. Contains unique investment opportunities, is diversified and trades at a discount to net asset value. https://nyemissioner.se/nyheter/investmentbolaget-linc-ar-fortsatt-kopvart-anser-dagens-industri/
- ·26.2.Interesting situation!i Linc? Large insider purchases recently and that they own approx. 15% of Medivir which has surged approx. 240 % while Linc has only moved a 5-7%. Realized some of the profit in Medivir and bought Linc today.
- ·25.2.Updated 25.02.2026 Is Linc still a good offer, after the share has risen 14-15 % from its low point to its high point in the last month? And when the price of Medcap keeps falling right now. When checking ibindex.se today, their calculation of the NAV discount on Linc now only shows 6 % at a share price as of today of 66.90 SEK. But that's not how I calculate the discount, as I instead use what I call the “real NAV discount”, and thus arrive at 63 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares as well as positive capital including receivables (and offsetting any debt.) So right now, you get the unlisted shares in Linc’s portfolio for one third of the valuation. (Today I have deleted a number of previous posts, as they were based on a NAV and a discount that were much higher at the time, so no one is “tricked” into believing that the discount is as large as it was when I wrote the post.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly determined. I do not have the prerequisites to know that, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. It can be noted that there are significant insider purchases, which have probably contributed to the price increase recently. But since the 15 unlisted shares in Linc only constitute approx. 10 % of the total NAV, it doesn't really matter much for this stock if one or two of these shares should be overpriced or go bankrupt. Another prerequisite is, of course, that one is comfortable with whether the daily price of the listed shares will hold up in the future to the same extent as other shares on the market, or whether one assesses that some of them have serious hidden problems. Others than me may have greater abilities to assess the value of the underlying unlisted companies. But an important detail is that Medcap accounts for 1/3 of the value in the Linc share. Medcap is relatively lowly priced at the moment, which can provide upside potential. If, on the other hand – dramatically – one assesses that the share could go bankrupt and end at 0 SEK, then it corresponds to the price of Linc being 29 % too high. But that is hardly a scenario anyone can imagine. But I choose to continuously monitor the price development in Medcap to assess Linc. I myself think it is an advantage to be invested in Medcap via Linc, so I have a large insurance through the diversification in Linc instead of being directly invested in Medcap myself – but that is probably a matter of taste. Is Linc still a good offer? Yes, I think so myself, based on an expectation that Medcap's price will rise again and that insiders, through their purchases, show their confidence in Linc. If one does not share these views, the matter is different. Linc is a somewhat peculiar stock. In periods, one pays an overprice, and in other periods, one gets a large discount. There are no fundamental reasons for the fluctuations, so one simply has to get used to them - and use them in one's buy and sell strategy. One of the very good things about this stock is that you don't have to worry about a dilutive rights issue, as we have seen in e.g. Karolinska Development and First Venture. On the contrary. The coffers are full.
- 25.2.25.2.Tämä julkaisu on poistettu.·23.1.So Affärsvärlden also entered the arena: is pointed out by Affärsvärlden as a healthy alternative in a long-term portfolio. Affärsvärlden issues a buy recommendation for Linc and states that the share is now trading at a record-high discount.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 73 | - | - | ||
| 250 | - | - | ||
| 4 | - | - | ||
| 40 | - | - | ||
| 286 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 659 | 14 659 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 659 | 14 659 | 0 | 0 |